Exenatide versus insulin glargine: A cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 8, 2009, Pages 501-515

  Brändle, Michael ^a   Erny Albrecht, K M ^b   Goodall, G ^b   Spinas, G A ^c   Streit, P ^d   Valentine, W J ^b  

^a Division of Endocrinology and Diabetes   (Switzerland)

^b IQVIA   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Eli Lilly SA   (Switzerland)

Author keywords

Cost effectiveness; Exenatide; Iinsulin glargine; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GLARGINE; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPUTER SIMULATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC RETINOPATHY; DRUG COST; FEMALE; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SWITZERLAND; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; PEPTIDES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SWITZERLAND; VENOMS;

EID: 70349115262     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47501     Document Type: Article

References (67)

1. Andreyeva T, van Michaud PC. Obesity and health in Europeans aged 50 years and older. Publ Health. 2007; 121: 497-509.
2. Australian Institute of Health and Welfare. The burden of disease and injury in Australia.
3. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005; 14: 217-230.
4. Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007; 45: 203-220.
5. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997; 6: 327-340.
6. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
7. Buse J, Macconell L, Stonehouse AH, Xuesong G, Malone J, Okerson T, Magges D, Kim D. Exenatide maintained glycemic control with associated weight reduction over three years in patients with Type 2 diabetes; 2007.
8. Calvert MJ, McManus RJ, Freemantle N. Management of Type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007; 57: 455-460.
9. Charpentier G, Genes N, Vaur L, Amar J, Clerson P, Cambou JP, Gueret P. Control of diabetes and cardiovascular risk factors in patients with Type 2 diabetes: a nationwide French survey. Diab Metab. 2003; 29: 152-158.
10. Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002; 22: 340-349.
11. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on health-care costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diab Med. 2003; 20: 442-450.
12. Coffey JT, Brändle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH. Valuing health-related quality of life in diabetes. Diabetes Care. 2002; 25: 2238-2243.
13. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diab Metab Res Rev. 1999; 15: 42-46.
14. DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann Intern Med. 1999; 131: 281-303.
15. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100.
16. Deutsche Diabetes Union. http://www.diabetes-union.de/2006; (Accessed April 2008).
17. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006; 368: 1696-1705.
18. Ess SM, Luscher TF, Szucs TD. High dose lisinopril in heart failure: economic considerations. Cardiovasc. Drugs Ther. 2002; 16: 365-371.
19. Fine JT, Colditz GA, Coakley EH, Moseley G, Manson JE, Willett WC, Kawachi I. A prospective study of weight change and health-related quality of life in women. JAMA. 1999; 282: 2136-2142.
20. Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with Type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006; 28: 388-395.
21. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity and (beta)-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005; 146: 2069-2076.
22. Gozzoli V, Palmer AJ, Brandt A, Spinas GA. Economic and clinical impact of alternative disease management strategies for secondary prevention in Type 2 diabetes in the Swiss setting. Swiss Med Wkly. 2001; 131: 303-310.
23. Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics. 2002; 20: 393-404.
24. Han TS, Tijhuis MA, Lean ME, Seidell JC. Quality of life in relation to overweight and body fat distribution. Am J Publ Health. 1998; 88: 1814-1820.
25. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143: 559-569.
26. Heller S. Weight gain during insulin therapy in patients with Type 2 diabetes mellitus. Diab Res Clin Pract. 2004; (65 Suppl. 1): S23-S27.
27. Henry RR, Ratner RE, Stonehouse AH, Xuesong G, Poon T, Malone JK, Kim DD, Kendall DM. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with Type 2 diabetes (abstract 485-P). 2006; A116.
28. Henzen C, Hodel T, Lehmann B, Mosimann T, Horler U, Joss R. Prevalence and therapy of vascular risk factors in hospitalized Type 2 diabetic patients. Schweiz Med Wochenschr. 2000; 130: 1979-1983.
29. Heo M, Allison DB, Faith MS, Zhu S, Fontaine KR. Obesity and quality of life: mediating effects of pain and comorbidities. Obes Res. 2003; 11: 209-216.
30. International Diabetes Federation. Facts and Figures: Did you know?; 2004.
31. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091.
32. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24: 275-286.
33. Koster I, Hauner H, von Ferber L. Heterogenität der Kosten bei Patienten mit Diabetes mellitus: Die KoDiM-Studie Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study. Dtsch Med Wochenschr. 2006; 131: 804-810.
34. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs. 2005; 65: 385-411.
35. Larsson U, Karlsson J, Sullivan M. Impact of overweight and obesity on health-related quality of life - a Swedish population study. Int J Obes Relat Metab Disord. 2002; 26: 417-424.
36. Lean ME, Han TS, Seidell JC. Impairment of health and quality of life using new US federal guidelines for the identification of obesity. Arch Intern Med. 1999; 159: 837-843.
37. Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005; 22: 1482-1486.
38. Matza L, Secnik K, Yurgin NR, Brewster-Jordan J, Shorr JM, Barber BL. Standard Gamble Assessment of Utilities for Type 2 Diabetes Treatment Related Attributes. 2006; submitted.
39. Morabia A, Costanza M. The obesity epidemic as harbinger of a metabolic disorder epidemic: trends in overweight, hypercholesterolemia, and diabetes treatment in Geneva, Switzerland, 1993-2003. Am J Publ Health. 2005; 95: 632-635.
40. NICE. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children;CG43FullGuideline6v.pdf CG43FullGuideline6v.pdf. 2007.
41. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of Type 2 diabetes. Curr Opin Invest Drugs. 2003; 4: 401-405.
42. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of Type 2 diabetes. Regul Pept. 2004; 117: 77-88.
43. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement mecision-making. Curr Med Res Opin. 2004a; 20: 5-26.
44. Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin. 2004b; 20: S27-S40.
45. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28: 2673-2679.
46. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993; 119: 655-660.
47. Pittrow D, Stalla GK, Zeiher AM, Silber S, Marz W, Pieper L, Klotsche J, Glaesmer H, Ruf G, Schneider HJ, Lehnert H, Bohler S, Koch U, Wittchen HU. Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care. Med Klin (Munich). 2006; 101: 635-644.
48. Prevost G, Phan TM, Mounier-Vehier C, Fontaine P. Control of cardiovascular risk factors in patients with Type 2 diabetes and hypertension in a French national study (Phenomen). Diab Metab. 2005; 31: 479-485.
49. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol. 2003; 2: 33-47.
50. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with Type 2 diabetes mellitus. Diab Obes Metab. 2006; 8: 419-428.
51. Ray JA, Boye KS, Yurgin NR, Valentine WJ, Roze S, McKendrink J, Tucker DM, Foos V, Palmer AJ. Exenatide versus insulin glargine in patients with Type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007; 23: 609-622.
52. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with Type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res. Rev. 2006; 22: 483-491.
53. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-3086.
54. Romon I, Fosse S, Lecomte P, Simon D, Fagot-Campagna A. Utilisation de lecteurs de glycemie, donnêes de l'êtude ENTRED, 2001-2002, Association Francaise des Diabetiques; 2007.
55. Sach TH, Barton GR, Doherty M, Muir KR, Jenkinson C, Avery AJ. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes (Lond). 2007; 31: 189-196.
56. Sandoz MS, Ess SM, Keusch GW, Schwenkglenks M, Szucs TD. Prevalence and direct medical costs of end-stage renal disease in patients with Type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly. 2004; 134: 448-458.
57. Schmitt-Koopman I, Schwenkglenks M, Szucs TD, Spinas G. Direct medical costs of Type 2 diabetes and its complications in Switzerland. Eur J Public Health. 2003; 14: 3-9.
58. Swiss Federal Government. 4th Revision of Disability Fund Law. 2004.
59. Tarmed 2006 www.fmh.ch/ww/de/pub/dienstleistungen/tarife/tarmed/ tarmed_browser.htm (Accessed April 2008).
60. Tarn T, Smith M. Pharmacoeconomic Guidelines Around the World. ISPOR Connections. 2004; 10: 5-15.
61. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000; 38: 583-637.
62. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
63. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005-2012.
64. UKPDS Group. UK Prospective Diabetes Study 16. Overview of 6-year therapy of Type II diabetes: a progressive disease. Diabetes. 1995; 44: 1249-1258.
65. UKPDS Group. Plasma lipids and lipoproteins at diagnosis of NIDDM: effects of age and gender (UKPDS 27). Diabetes Care. 20: 1683-1687.
66. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002; 45: S13-S17.
67. Wilson PW, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol. 1994; 49: M252-M257.